IL6 and ovarian carcinoma: Lycopene status had no effect on preeclampsia [54], early age-related macular degeneration [46], risk of hip fracture [55], advanced prostate cancer [34,56], colon/colorectal/rectal cancer [49], bladder cancer [42], gastric cancer [57], non-Hodgkin lymphoma [48], ovarian cancer [58], Parkinson’s disease [47], inflammatory biomarkers (except a small effect in interleukin-6 (MD −1.08 pg/mL; 95% CI −2.03, −0.12) [37], lipid profiles [59,60], blood pressure [60] and prostate specific antigen (PSA) levels [61] (Table S3).